The risk of tuberculosis infection in 410 Saudipatients receiving adalimumab therapy
BACKGROUND: Adalimumab is a fully humanized monoclonal antibody inhibitor of tumor necrosis factor-a used to treat various autoimmune disorders. Adalimumab poses a risk for tuberculosis (TB) infection, especially in countries where TB is endemic. OBJECTIVE: Determine the rate of TB infection after a...
Guardado en:
| Autores principales: | , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
King Faisal Specialist Hospital and Research Centre
2021
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/509a4578978a4742b75b0e1ee2ff05a3 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|